This website uses cookies, including third party ones, to allow for analysis of how people use our website in order to improve your experience and our services. By continuing to use our website, you agree to the use of such cookies. Click here for more information on our and .
Healthcare
Diabetes pipeline cannot reverse cardiovascular and metabolic market decline
Melbourne, 10th February 2011 - Strong diabetes growth will not be enough to stop the cardiovascular and metabolic market from declining, finds independent market analyst Datamonitor.* Datamonitor forecasts that the cardiovascular and metabolic market across the seven major markets** will peak in 2011 and then begin to decline, with total sales falling from $105bn in…
10 Feb 2011, by Informa InsightsHealthcare
Can India become a biosimilar powerhouse?
Melbourne, 8th February 2011 - Indian manufacturers are ideally placed to capitalise on the growing biosimilars market, according to independent market analyst Datamonitor. Although the biosimilars market is in its infancy, Datamonitor research suggests that Indian manufacturers are well positioned to capitalise on the future growth of this market both domestically and internationally. Alistair Sinclair,…
8 Feb 2011, by Informa InsightsHealthcare
Rapidly deteriorating growth for Pharma
Melbourne, 21st January 2011. Growth will slow to just 1.3% to 2015 for the branded prescription pharmaceutical industry’s leading companies, according to latest research from independent market analyst, Datamonitor. Between 2003 and 2009, theses same companies enjoyed robust sales growth at a compound annual growth rate (CAGR) of 7.1%. Sharp declines in branded sales following…
21 Jan 2011, by Informa InsightsHealthcare
Stigma remains over Major Depressive Disorder
Melbourne, 12th January 2011 - Despite there being 39.1 million people suffering from major depressive disorder (MDD) across the seven major markets, only one third of patients will seek help from a physician, finds latest research from independent analyst Datamonitor*. Daniel Chancellor, healthcare analyst at Datamonitor, comments: “This is due to the stigma that is…
12 Jan 2011, by Informa InsightsHealthcare
Driven by strong market growth, Big Pharma’s interest in China is set to increase
Melbourne, 15th December 2010 – Rapid population growth as well as the increasing number of elderly people in China have created additional pressure on the government in terms of healthcare provision. In order to improve healthcare access, the Chinese government will spend $124.6 billion on healthcare reforms between 2009 and 2011 according to the latest…
15 Dec 2010, by Informa InsightsHealthcare
Smartphones and tablets will aid consumerisation of healthcare in 2011
Melbourne, 6th December 2010. Consumer-driven healthcare will gather momentum in 2011 as the public takes more responsibility for its own health, with technology playing a key role, according to Ovum. In a new report* the independent technology analyst states that devices such as smartphones and tablet computers will help to drive the consumerisation of healthcare…
6 Dec 2010, by Informa InsightsHealthcare
Disappointing year for Roche but restructuring will help maintain strong fiscal position
Melbourne, 18th November 2010 - John Bird, pharmaceutical company analyst at Datamontior, comments on Roche’s plans to cut 6 percent of its global workforce, or 4800 jobs, over the next two years as part of efforts to make annual cost savings of $2.4 billion: “Many Big Pharma companies have restructured in recent times due to…
18 Nov 2010, by Informa InsightsHealthcare
Market development key for testosterone replacement therapy
Melbourne, 17th November 2010 - Despite growing at a compound annual growth rate of more than 24% over the last five years, the testosterone replacement therapy market is severely underdeveloped. This suggests there are great opportunities for pharmaceutical companies in this field, claims independent market analyst, Datamonitor*. The testosterone replacement therapy market, valued at $838m…
17 Nov 2010, by Informa InsightsHealthcare
Can Pfizer rescue hormonal replacement therapy?
Melbourne, 17th November 2010 - In a market still plagued with safety concerns, Pfizer has an opportunity to restore market growth for hormonal replacement therapy (HRT) with its new combination product, Aprela. To do this it must rebuild public and general practitioner confidence in the therapy area, says independent market analyst, Datamonitor*. The value of…
17 Nov 2010, by Informa InsightsHealthcare
Pfizer to acquire King Pharmaceuticals for $3.6 billion.
Expert comment from Datamonitor principal analyst Simon King: “The King acquisition represents a small but integral part of a broader diversification strategy that continues to be implemented by Pfizer. This strategy has to date encompassed the multi-billion dollar acquisition of Wyeth but also various in-licensing agreements and a concerted movement into the generics market as…
15 Oct 2010, by Informa InsightsInforma Connect Australia is the nation's leading event organiser. Our events comprise of large scale exhibitions, industry conferences and highly specialised corporate training.
